Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer

Published:2015 Issue:3 Volume:89 Page:152-158
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Mizushima Tsunekazu^ORCID,Tamagawa Hiroshi,Matsuda Chu,Murata Kohei,Fukunaga Mutsumi,Ota Hirofumi,Hasegawa Junichi,Tsujie Masaki,Fukuzaki Takayuki,Hata Taishi,Takemasa Ichiro,Ikeda Masataka,Yamamoto Hirofumi,Sekimoto Mitsugu,Nezu Riichiro,Doki Yuichiro,Mori Masaki

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years;Japanese Journal of Clinical Oncology;2022-04-25

2. Oncologic Outcome and Efficacy of Chemotherapy in Colorectal Cancer Patients Aged 80 Years or Older;Frontiers in Medicine;2020-10-23

3. Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER);International Journal of Clinical Oncology;2019-05-14

4. Oncologic outcome of colorectal cancer patients over age 80: a propensity score-matched analysis;International Journal of Colorectal Disease;2018-03-21

5. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer;International Journal of Cancer;2016-04-23